ArticleThoracic cancer2026
RETRACTION: FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionL. Zhang, Y. Mao, Q. Mao, W. Fan, L. Xu, Y. Chen, L. Xu and J. Wang, "FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma," Thoracic Cancer 10, no. 4 (2019): 909-917, https://doi.org/10.1111/1759-7714.13027. The above article, published online on 05 March 2019 in Wiley Online Library (wileyonlinelibrary.com), and its correction, (https://doi.org/10.1111/1759-7714.14990), has been retracted by agreement between the journal Editor-in-Chief, Tateaki Naito; and John Wiley & Sons Australia, Ltd. The retraction has been agreed upon following concerns raised by a third party. An investigation identified duplication between the OEFLOT1_NC flow cytometry plot presented in Figure 2f of this article and a plot published previously by a different author group. The authors were contacted for comment and supporting data, but did not respond. In light of these findings, the editors consider the results and conclusions to be unreliable. The authors did not respond to our notice of retraction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.